Serum sRAGE Levels Link Biological Rhythm Stability to Depression Severity

Circadian Dysregulation and the Molecular Architecture of Depression

Major depressive disorder remains a leading cause of global disability, driven by a complex interplay of neurotransmitter imbalances, hypothalamic-pituitary-adrenal axis dysregulation, and systemic inflammation [1, 2]. Beyond primary mood symptoms, patients frequently experience profound disruptions in biological rhythms, which are increasingly recognized as central to the disease's progression and persistence [3]. These circadian disturbances often manifest as severe insomnia and altered physiological variability, complicating the clinical management of depressive episodes [4, 5]. While various metabolic pathways and immune signals have been implicated in these systemic shifts, the specific molecular bridges linking rhythm stability to psychiatric health remain poorly defined [6]. A new study now investigates a specific circulating receptor that may clarify the relationship between immune signaling and biological rhythm regulation in clinical populations.

Quantifying Clinical and Biochemical Markers

The researchers conducted a case-control study to examine the relationship between serum biomarkers and circadian stability, enrolling a cohort of 73 patients diagnosed with major depressive disorder and 48 healthy controls. To establish a comprehensive clinical profile, the authors utilized a self-designed demographic questionnaire alongside several validated psychometric instruments. These included the Hamilton Depression Rating Scale-24 to quantify the depth of depressive symptoms and the Hamilton Anxiety Rating Scale-14 to assess comorbid anxiety levels. Given the high prevalence of sleep disturbances and self-harm risk in this population, the researchers also administered the Insomnia Severity Index and the Self-Rating Idea of Suicide Scale to capture specific behavioral phenotypes. Beyond primary psychiatric symptoms, the study evaluated environmental and physiological factors that influence the disease course. The Social Support Rating Scale was used to measure the patients' perceived external resources, while a critical component of the methodology involved the Biological Rhythms Interview of Assessment in Neuropsychiatry. This clinical tool allowed the researchers to quantify disruptions across five domains, including sleep, activities, social rhythm, eating patterns, and chronotype (an individual's natural inclination regarding the timing of sleep and wakefulness), providing a standardized metric for biological rhythm disruption that goes beyond subjective patient reports. To identify the molecular underpinnings of these clinical observations, the researchers analyzed serum samples using Luminex multiplex bead-based immunoassays, a high-throughput technique that allows for the simultaneous quantification of multiple proteins in a single sample. The panel specifically targeted four biomarkers: S100A8 and S100A9, which are calcium-binding proteins involved in inflammatory signaling; interleukin-10, an anti-inflammatory cytokine; and soluble receptor for advanced glycation end products (sRAGE). By measuring sRAGE, which acts as a decoy receptor to prevent the activation of pro-inflammatory pathways, the study sought to determine how these biochemical markers correlate with the clinical severity of depression and the degree of circadian dysregulation.

The Burden of Rhythm Disruption in Clinical Depression

The comparative analysis between the 73 patients with major depressive disorder and the 48 healthy controls revealed a profound divergence in physiological and behavioral stability. Patients with major depressive disorder exhibited severe biological rhythm disruptions compared to healthy controls (t = 9.651), a finding that underscores the systemic nature of the disease beyond primary mood symptoms. This instability in the internal clock, which governs sleep-wake cycles and metabolic processes, was closely mirrored by objective sleep disturbances. Specifically, the researchers found that patients demonstrated significant insomnia versus the control group (t = 9.688), suggesting that the breakdown of circadian regulation is a core feature of the clinical presentation in this cohort. The clinical burden extended into the psychiatric and social domains, where the differences between the two groups remained stark. The researchers observed significant anxiety in the patient group compared to healthy controls (t = 17.383), representing the highest statistical variance among the measured clinical parameters. This high level of comorbid anxiety was accompanied by a critical increase in self-harm risk, as major depressive disorder patients exhibited significant suicidal ideation versus healthy controls (t = 11.127). Furthermore, the study identified a deficit in the patients' external environment, noting that depressed individuals experienced reduced social support compared to the control group (t = -3.307). Together, these findings illustrate a multifaceted clinical profile where biological rhythm instability coincides with heightened psychological distress and a weakened social safety net, suggesting that stabilizing these rhythms may be essential for comprehensive recovery.

sRAGE as a Protective Mediator of Circadian Health

The molecular mechanisms underlying circadian stability involve the receptor for advanced glycation end products (RAGE), a transmembrane protein that, upon activation, triggers the nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) and mitogen-activated protein kinase (MAPK) signaling pathways. These specific intracellular pathways are critically implicated in the regulation of biological rhythms, serving as a bridge between systemic inflammation and the internal clock. While the receptor itself is membrane-bound, it also exists as a circulating isoform known as serum soluble RAGE (sRAGE). Altered levels of this soluble form have been documented across a spectrum of somatic and neuropsychiatric conditions, including major depressive disorder, suggesting that sRAGE may modulate the inflammatory signaling that otherwise disrupts physiological cycles. To determine the predictive value of these markers, the researchers utilized stepwise linear regression (a statistical method that identifies the most significant predictors of an outcome by adding or removing variables) to identify the primary drivers of circadian instability. The results showed that depression (β = 0.347) and insomnia (β = 0.367) were significant predictive factors for biological rhythm disruptions, indicating that as the severity of these clinical symptoms increases, the stability of the patient's internal rhythm decreases. Conversely, the analysis revealed that sRAGE was also a predictive factor for biological rhythm disruptions (β = -0.223), but with an inverse relationship. This negative beta coefficient suggests that higher levels of the soluble receptor are associated with lower levels of rhythm disruption, pointing toward a potential buffering effect against the physiological stressors of the disease. Further mediation analysis (a statistical technique used to identify the mechanism through which an independent variable influences a dependent variable) clarified the specific roles of these variables in the pathology of major depressive disorder. The researchers identified that insomnia and sRAGE both function as mediators of biological rhythm disruption in patients (p < 0.05). Within this framework, sRAGE demonstrated a beneficial role in the mediation of biological rhythm disruption (β = -0.21), acting as a protective factor. These findings suggest that sRAGE may be favorably associated with major depressive disorder by mitigating disruptions in biological rhythms. For the practicing clinician, this identifies sRAGE as a potential biochemical marker for predicting and managing depressive episodes, as its presence may help stabilize the circadian framework that is so frequently compromised in depressed patients.

References

1. Cui L, Li S, Wang S, et al. Major depressive disorder: hypothesis, mechanism, prevention and treatment. Signal Transduction and Targeted Therapy. 2024. doi:10.1038/s41392-024-01738-y

2. Yim IS, Stapleton LRT, Guardino CM, Hahn‐Holbrook J, Schetter CD. Biological and Psychosocial Predictors of Postpartum Depression: Systematic Review and Call for Integration. Annual Review of Clinical Psychology. 2015. doi:10.1146/annurev-clinpsy-101414-020426

3. Zhang Y, Liu C, Zhu Q, Wu H, Liu Z, Zeng L. Relationship Between Depression and Epigallocatechin Gallate from the Perspective of Gut Microbiota: A Systematic Review. Nutrients. 2025. doi:10.3390/nu17020259

4. Shaffer F, Ginsberg JP. An Overview of Heart Rate Variability Metrics and Norms. Frontiers in Public Health. 2017. doi:10.3389/fpubh.2017.00258

5. Oh DL, Jerman P, Marques SS, et al. Systematic review of pediatric health outcomes associated with childhood adversity. BMC Pediatrics. 2018. doi:10.1186/s12887-018-1037-7

6. Loh JS, Mak WQ, Tan L, et al. Microbiota–gut–brain axis and its therapeutic applications in neurodegenerative diseases. Signal Transduction and Targeted Therapy. 2024. doi:10.1038/s41392-024-01743-1